Navigation Links
University of Colorado Cancer Center test helps reduce risk of death in advanced lung cancer
Date:10/11/2011

AURORA, Colo. (Oct. 11, 2011) Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30- month period in a recent clinical trial.

"We are moving from a one-size-fits-all model to more personalized medicine in lung cancer," said University of Colorado School of Medicine Professor Fred R. Hirsch, MD, Ph.D., a Cancer Center investigator who developed the test along with colleague Wilbur Franklin, MD. "This is a completely new paradigm in treating cancer."

The test was developed in 2003 when Hirsch and his colleagues created a scoring system ranging from 0 to 400 that identified patients with the highest levels of the protein Epidermal Growth Factor Receptor (EGFR). Those scoring over 200 had a better prognosis.

A clinical trial held in Europe known as the FLEX-study, found that 30 percent of the advanced lung cancer patients who took part had high levels of the EGFR protein identified by the University of Colorado Cancer Center test.

The trial consisted of 1,125 advanced lung cancer patients separated into two groups. One group received standard chemotherapy while the other had chemotherapy along with the drug cetuximab, an antibody that attaches to EGFR receptors atop lung cancer cells and often inhibits their growth.

The results were announced two weeks ago at the 2011 European Multidisciplinary Cancer Conference in Stockholm.

Using the Cancer Center test, the trial showed that Caucasian patients with an over expression of EGFR and treated with chemotherapy and cetuximab had a 36 percent reduction in deaths compared to the other group.

Cetuximab, or Erbitux, is primarily used to fight colo-rectal and head and neck cancers.

Hirsch, who discussed the study results at the Stockholm conference, said the test is another step toward finding the best, most effective therapy for each patient.

"With this personalized medicine we can identify subgroups of patients that can get better effects from certain drugs," he said. "In some cases there is a potential for a cure. Right now the cure rate for advanced lung cancer is two to three percent at best. This is a huge improvement but everything is based on the selection criteria."

The CU School of Medicine is a prominent leader in lung cancer research. D. Ross Camidge, MD, Ph.D., clinical director of the Thoracic Oncology Program at the University of Colorado Hospital and a Cancer Center investigator, has helped develop effective drug treatments for patients with the ALK gene rearrangement, an abnormality that occurs in three to five percent of lung cancer patients.

Hirsch is currently leading a clinical trial with colleagues in the Southwest Oncology Group that is similar to the European study. He hopes it will further validate the predictive value of the test in relation to using cetuximab in patients with advanced lung cancer. The study (SWOG 0819) has 550 participants and expects 1,500 total.

Hirsch's research laboratory specializes in identifying biomarkers which can predict benefits from new cancer drugs and place the right patients with the right therapy.


'/>"/>

Contact: David Kelly
david.kelly@ucdenver.edu
30-303-156-374
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
2. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
3. Most pandemic plans in Ontario hospitals have not been tested: Queens University study
4. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
5. Smithsonian Institution, Arizona State University announce education and research partnership
6. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
7. Giarmarco, Mullins & Horton, P.C. President Joseph F. Page to Speak at University of Michigan
8. Arizona State Universitys Decision Theater offers balance to an off-kilter world
9. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
10. Herzing University Online Launches Master and Bachelor of Science Degrees in Nursing
11. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 05, 2016 , ... Health and wellness is a topic that should concern ... they are experiencing an illness. Migraines are a severe form of a headache and ... would not wish the pain on their worst enemy, the feeling can last for ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... Care for Patients with Rare Diseases, a continuing medical education (CME) event presented ... the first of its kind—and a first for ACCORD, whose mission is to ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ) ... event in New York City on Thursday, January 21, 2016. Kingsley R. ... (both alumnus of the varsity Columbia soccer program) spoke at the event, offering ...
(Date:2/5/2016)... ... 05, 2016 , ... Susan Polk Health Insurance Company recently released ... to see in 2016. To view the report, see below, or visit Susan ... San Luis Obispo seniors who rely on Medicare health insurance and whose monthly income ...
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... the "It's All About YOU Re-Treat" on February 19-21, 2016, in Southern ... is at Rancho Palos Verdes, California. These 30 professional speakers, including Clinical Psychologist ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 Summary ... most common cancer and the most common cancer in ... making the disease exceedingly prevalent. The number of women ... few decades, but the number of deaths has declined ... Breast cancer treatment has been revolutionized in the past ...
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 3% as currency reduced sales growth ... per diluted share as reported (EPS) were $4.44, compared ... was $4.65, an increase of 10% over the prior-year ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology: